
Release date: 2026-06-18 11:12:41 Article From: Lucius Laos Recommended: 8
The recommended dose is 2 tablets (i.e., 450 mg) orally once daily, taken with or shortly after a meal to ensure adequate absorption. This dose may be continued long-term as long as clinical benefit is observed and adverse reactions are tolerable. If intolerable toxicity occurs, the physician may reduce the dose to 1 tablet (225 mg) daily or temporarily interrupt treatment for a few days until symptoms resolve, then resume. Do not adjust the dose on your own.
For patients who have difficulty swallowing tablets, place 2 tablets in a cup, add 30 mL of room-temperature water (non-carbonated), and stir for several minutes until the tablets disintegrate into small particles (they will not completely dissolve). Drink the suspension within 1 hour. To ensure the full dose is taken, rinse the cup with another 30 mL of water and drink it. If the patient has a nasogastric tube of at least 8 French gauge, prepare the suspension in the same manner and push it through the tube within 1 hour, then flush the cup and syringe twice with 30 mL of water each time to ensure no drug residue remains and the entire dose has been delivered.
If you forget to take a dose, take it as soon as you remember; however, if it is less than 8 hours until your next scheduled dose, skip the missed dose and take the next one at the regular time. Never double the dose to make up for a missed one. Regarding overdose, clinical experience is limited, but it is presumed that overdose symptoms may resemble common adverse reactions (such as nausea, diarrhea, edema, etc.). If you suspect an overdose, contact your doctor immediately for timely assessment and management.
On November 21, 2025, the U.S. Food and Drug Administration (FDA) approved the regimen of pembrolizu···【more】
Recommended:4572025-17-12
Lung cancer is the most rapidly increasing malignant tumor with the fastest increasing morbidity and···【more】
Recommended:6392024-09-07
On May 28, 2026, AstraZeneca announced that its immunotherapy drug Imfinzi (durvalumab) in combinati···【more】
Recommended:972026-01-06
On December 12, 2025, the U.S. Food and Drug Administration (FDA) approved niraparib in combination ···【more】
Recommended:4182025-15-12
The U.S. Food and Drug Administration (FDA) announced today that it has approved Omisirge (omidubice···【more】
Recommended:4432025-10-12
On December 4, 2025, the U.S. Food and Drug Administration (FDA) approved lisocabtagene maraleucel (···【more】
Recommended:4282025-08-12
On December 3, 2025, the U.S. Food and Drug Administration (FDA) granted full approval to pirtobruti···【more】
Recommended:4832025-04-12
Primary analysis data from the randomized, double-blind, placebo-controlled phase III HER2CLIMB-02 s···【more】
Recommended:3932025-01-12

Lucius Pharmaceutical Co., Ltd., was established in 2020 in Vientiane, the capital of Laos. It aims to offer safe, effective, and affordable medicines globally. With a factory spanning 25,000 square meters, the company manufactures 200+ generic drugs in diverse therapeutic fields.
Address: No.26 Thongmang village, Xaythany district, Vientiane Capital, Laos
E-mail:laoslucius@gmail.com

Name: Lucius

Telegram name: Vira
No.:0085253923643
Telegram name: Vira
No.:0085253923643